• Je něco špatně v tomto záznamu ?

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis

T. Kalincik, V. Jokubaitis, T. Spelman, D. Horakova, E. Havrdova, M. Trojano, J. Lechner-Scott, A. Lugaresi, A. Prat, M. Girard, P. Duquette, P. Grammond, C. Solaro, F. Grand'Maison, R. Hupperts, J. Prevost, P. Sola, D. Ferraro, M. Terzi, E....

. 2018 ; 24 (12) : 1617-1626. [pub] 20170831

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu srovnávací studie, časopisecké články, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035587

OBJECTIVE: This propensity score-matched analysis from MSBase compared the effectiveness of cladribine with interferon β, fingolimod or natalizumab. METHODS: We identified all patients with relapse-onset multiple sclerosis, exposure to the study therapies and ⩾1-year on-treatment follow-up from MSBase. Three pairwise propensity score-matched analyses compared treatment outcomes over 1 year. The outcomes were hazards of first relapse, disability accumulation and disability improvement events. Sensitivity analyses were completed. RESULTS: The cohorts consisted of 37 (cladribine), 1940 (interferon), 1892 (fingolimod) and 1410 patients (natalizumab). The probability of experiencing a relapse on cladribine was lower than on interferon ( p = 0.05), similar to fingolimod ( p = 0.31) and higher than on natalizumab ( p = 0.042). The probability of disability accumulation on cladribine was similar to interferon ( p = 0.37) and fingolimod ( p = 0.089) but greater than natalizumab ( p = 0.021). The probability of disability improvement was higher on cladribine than interferon ( p = 0.00017), fingolimod ( p = 0.0025) or natalizumab ( p = 0.00099). Sensitivity analyses largely confirmed the above results. CONCLUSION: Cladribine is an effective therapy for relapse-onset multiple sclerosis. Its effect on relapses is comparable to fingolimod and its effect on disability accrual is comparable to interferon β and fingolimod. Cladribine may potentially associate with superior recovery from disability relative to interferon, fingolimod and natalizumab.

Brain and Mind Centre Sydney NSW Australia

CISSS de Chaudière Appalache Levis QC Canada

Clinique Neuro Rive Sud Greenfield Park QC Canada

CORe Department of Medicine The University of Melbourne Melbourne VIC Australia Department of Neurology The Royal Melbourne Hospital Melbourne VIC Australia

CSSS de Saint Jérôme Saint Jerome QC Canada

Department of Basic Medical Sciences Neuroscience and Sense Organs University of Bari Bari Italy

Department of Neurology and Center of Clinical Neuroscience General University Hospital and Charles University Prague Prague Czech Republic

Department of Neurology The Royal Melbourne Hospital Melbourne VIC Australia Department of Medicine The University of Melbourne Melbourne VIC Australia

Department of Neurology The Royal Melbourne Hospital Melbourne VIC Australia Department of Medicine The University of Melbourne Melbourne VIC Australia Department of Neurology Box Hill Hospital Monash University Melbourne VIC Australia

Department of Neuroscience Imaging and Clinical Sciences University G d'Annunzio Chieti Italy Department of Biomedical and Neuromotor Sciences University of Bologna Bologna Italy IRCCS Istituto delle Scienze Neurologiche di Bologna Bologna Italy

Flinders University Adelaide SA Australia

Geelong Hospital Geelong VIC Australia

Hôpital Notre Dame Montreal QC Canada CHUM Universite de Montreal Montreal QC Canada

Liverpool Hospital Sydney NSW Australia

Medical Faculty 19 Mayis University Samsun Turkey

Monash Medical Centre Melbourne VIC Australia

Nuovo Ospedale Civile Sant'Agostino Estense Modena Italy

Ospedale Padre Antero Micone Genoa Italy

The Perron Institute The University of Western Australia Perth WA Australia

The Perron Institute The University of Western Australia Perth WA Australia Institute for Immunology and Infectious Diseases Murdoch University Perth WA Australia

The University of Newcastle Newcastle NSW Australia

The University of Queensland Brisbane QLD Australia Royal Brisbane and Women's Hospital Herston QLD Australia

Zuyderland Ziekenhuis Sittard The Netherlands

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035587
003      
CZ-PrNML
005      
20191015105153.0
007      
ta
008      
191007s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/1352458517728812 $2 doi
035    __
$a (PubMed)28857680
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kalincik, Tomas $u CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia/Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
245    10
$a Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis / $c T. Kalincik, V. Jokubaitis, T. Spelman, D. Horakova, E. Havrdova, M. Trojano, J. Lechner-Scott, A. Lugaresi, A. Prat, M. Girard, P. Duquette, P. Grammond, C. Solaro, F. Grand'Maison, R. Hupperts, J. Prevost, P. Sola, D. Ferraro, M. Terzi, E. Butler, M. Slee, A. Kermode, M. Fabis-Pedrini, P. McCombe, M. Barnett, C. Shaw, S. Hodgkinson, H. Butzkueven, MSBase Study Group,
520    9_
$a OBJECTIVE: This propensity score-matched analysis from MSBase compared the effectiveness of cladribine with interferon β, fingolimod or natalizumab. METHODS: We identified all patients with relapse-onset multiple sclerosis, exposure to the study therapies and ⩾1-year on-treatment follow-up from MSBase. Three pairwise propensity score-matched analyses compared treatment outcomes over 1 year. The outcomes were hazards of first relapse, disability accumulation and disability improvement events. Sensitivity analyses were completed. RESULTS: The cohorts consisted of 37 (cladribine), 1940 (interferon), 1892 (fingolimod) and 1410 patients (natalizumab). The probability of experiencing a relapse on cladribine was lower than on interferon ( p = 0.05), similar to fingolimod ( p = 0.31) and higher than on natalizumab ( p = 0.042). The probability of disability accumulation on cladribine was similar to interferon ( p = 0.37) and fingolimod ( p = 0.089) but greater than natalizumab ( p = 0.021). The probability of disability improvement was higher on cladribine than interferon ( p = 0.00017), fingolimod ( p = 0.0025) or natalizumab ( p = 0.00099). Sensitivity analyses largely confirmed the above results. CONCLUSION: Cladribine is an effective therapy for relapse-onset multiple sclerosis. Its effect on relapses is comparable to fingolimod and its effect on disability accrual is comparable to interferon β and fingolimod. Cladribine may potentially associate with superior recovery from disability relative to interferon, fingolimod and natalizumab.
650    _2
$a dospělí $7 D000328
650    _2
$a kladribin $x terapeutické užití $7 D017338
650    _2
$a kohortové studie $7 D015331
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fingolimod hydrochlorid $x terapeutické užití $7 D000068876
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    _2
$a interferon beta $x terapeutické užití $7 D016899
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
650    _2
$a natalizumab $x terapeutické užití $7 D000069442
650    _2
$a tendenční skóre $7 D057216
650    _2
$a recidiva $7 D012008
650    _2
$a výsledek terapie $7 D016896
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jokubaitis, Vilija $u Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia/Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia.
700    1_
$a Spelman, Tim $u Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia/Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia.
700    1_
$a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, General University Hospital and Charles University in Prague, Prague, Czech Republic.
700    1_
$a Havrdova, Eva $u Department of Neurology and Center of Clinical Neuroscience, General University Hospital and Charles University in Prague, Prague, Czech Republic.
700    1_
$a Trojano, Maria $u Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy.
700    1_
$a Lechner-Scott, Jeannette $u The University of Newcastle, Newcastle, NSW, Australia.
700    1_
$a Lugaresi, Alessandra $u Department of Neuroscience, Imaging and Clinical Sciences, University "G. d'Annunzio", Chieti, Italy/ Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy/IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
700    1_
$a Prat, Alexandre $u Hôpital Notre-Dame, Montreal, QC, Canada/CHUM, Universite de Montreal, Montreal, QC, Canada.
700    1_
$a Girard, Marc $u Hôpital Notre-Dame, Montreal, QC, Canada/CHUM, Universite de Montreal, Montreal, QC, Canada.
700    1_
$a Duquette, Pierre $u Hôpital Notre-Dame, Montreal, QC, Canada/CHUM, Universite de Montreal, Montreal, QC, Canada.
700    1_
$a Grammond, Pierre $u CISSS de Chaudière-Appalache, Levis, QC, Canada.
700    1_
$a Solaro, Claudio $u Ospedale Padre Antero Micone, Genoa, Italy.
700    1_
$a Grand'Maison, Francois $u Clinique Neuro Rive-Sud, Greenfield Park, QC, Canada.
700    1_
$a Hupperts, Raymond $u Zuyderland Ziekenhuis, Sittard, The Netherlands.
700    1_
$a Prevost, Julie $u CSSS de Saint-Jérôme, Saint-Jerome, QC, Canada.
700    1_
$a Sola, Patrizia $u Nuovo Ospedale Civile Sant'Agostino-Estense, Modena, Italy.
700    1_
$a Ferraro, Diana $u Nuovo Ospedale Civile Sant'Agostino-Estense, Modena, Italy.
700    1_
$a Terzi, Murat $u Medical Faculty, 19 Mayis University, Samsun, Turkey.
700    1_
$a Butler, Ernest $u Monash Medical Centre, Melbourne, VIC, Australia.
700    1_
$a Slee, Mark $u Flinders University, Adelaide, SA, Australia.
700    1_
$a Kermode, Allan $u The Perron Institute, The University of Western Australia, Perth, WA, Australia/Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA, Australia.
700    1_
$a Fabis-Pedrini, Marzena $u The Perron Institute, The University of Western Australia, Perth, WA, Australia.
700    1_
$a McCombe, Pamela $u The University of Queensland, Brisbane, QLD, Australia/Royal Brisbane and Women's Hospital, Herston, QLD, Australia.
700    1_
$a Barnett, Michael $u Brain and Mind Centre, Sydney, NSW, Australia.
700    1_
$a Shaw, Cameron $u Geelong Hospital, Geelong, VIC, Australia.
700    1_
$a Hodgkinson, Suzanne $u Liverpool Hospital, Sydney, NSW, Australia.
700    1_
$a Butzkueven, Helmut $u Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia/Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia/Department of Neurology, Box Hill Hospital, Monash University, Melbourne, VIC, Australia.
710    2_
$a MSBase Study Group
773    0_
$w MED00006389 $t Multiple sclerosis (Houndmills, Basingstoke, England) $x 1477-0970 $g Roč. 24, č. 12 (2018), s. 1617-1626
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28857680 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191015105618 $b ABA008
999    __
$a ok $b bmc $g 1452247 $s 1074137
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 24 $c 12 $d 1617-1626 $e 20170831 $i 1477-0970 $m Multiple sclerosis $n Mult Scler $x MED00006389
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace